Patents by Inventor Carsten Ryttersgaard
Carsten Ryttersgaard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9586961Abstract: The invention relates to compounds of general formula (I) wherein R1, R2, R3, R4, m and n are defined as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, as JAK kinase and protein tyrosine kinase inhibitors for preventing, treating or ameliorating diseases and complications thereof, including, for example, psoriasis, atopic dermatitis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes, asthma, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases and indications where immuno-suppression would be desirable for example in organ transplantation.Type: GrantFiled: July 8, 2011Date of Patent: March 7, 2017Assignee: LEO PHARMA A/SInventors: Simon Felbdæk Nielsen, Daniel R. Greve, Gunnar Grue-Sørensen, Carsten Ryttersgaard, Søren Christian Schou, Anette Graven Sams
-
Patent number: 9422309Abstract: The present invention relates to a compound according to formula (I) wherein R1 represents optionally substituted heteroaryl, and pharmaceutically acceptable salts, hydrates, solvates or pharmaceutically acceptable and physiologically cleavable esters thereof. The invention relates further to intermediates for the preparation of said compounds, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. diseases associated with hyperplasia, neoplasia or dysplasia, with said compounds, to methods of treatment of cosmetic indications with said compounds, and to the use of said compounds in the manufacture of medicaments.Type: GrantFiled: June 21, 2013Date of Patent: August 23, 2016Assignee: LEO LABORATORIES LIMITEDInventors: Xifu Liang, Thomas Högberg, Bjarne Nørremark, Kristoffer Månsson, Carsten Ryttersgaard, Gunnar Grue-Sørensen
-
Patent number: 9346809Abstract: The invention relates to compounds of general formula (I) wherein A, R1, R2, R3, R4, R5, R9, m and n are defined as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, as JAK kinase and protein tyrosine kinase inhibitors for preventing, treating or ameliorating diseases and complications thereof, including, for example, psoriasis, atopic dermatitis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes, asthma, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases and indications where immunosuppression would be desirable for example in organ transplantation.Type: GrantFiled: July 8, 2010Date of Patent: May 24, 2016Assignee: LEO PHARMA A/SInventors: Simon Feldbæk Nielsen, Daniel Rodriguez Greve, Carsten Ryttersgaard, Gunnar Grue-Sørensen, Erik Rytter Ottosen, Tina Dahlerup Poulsen, Søren Christian Schou, Anthony Murray
-
Publication number: 20150175622Abstract: The present invention relates to a compound according to formula (I) wherein R1 represents optionally substituted heteroaryl, and pharmaceutically acceptable salts, hydrates, solvates or pharmaceutically acceptable and physiologically cleavable esters thereof. The invention relates further to intermediates for the preparation of said compounds, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. diseases associated with hyperplasia, neoplasia or dysplasia, with said compounds, to methods of treatment of cosmetic indications with said compounds, and to the use of said compounds in the manufacture of medicaments.Type: ApplicationFiled: June 21, 2013Publication date: June 25, 2015Applicant: LEO LABORATORIES LIMITEDInventors: Xifu Liang, Thomas Högberg, Bjarne Nørremark, Kristoffer Månsson, Carsten Ryttersgaard, Gunnar Grue-Sørensen
-
Publication number: 20130172325Abstract: The invention relates to compounds of general formula (I) wherein R1, R2, R3, R4, m and n are defined as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, as JAK kinase and protein tyrosine kinase inhibitors for preventing, treating or ameliorating diseases and complications thereof, including, for example, psoriasis, atopic dermatitis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes, asthma, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases and indications where immuno-suppression would be desirable for example in organ transplantation.Type: ApplicationFiled: July 8, 2011Publication date: July 4, 2013Applicant: LEO PHARMA A/SInventors: Simon Felbdæk Nielsen, Daniel R. Greve, Gunnar Grue-Sorensen, Carsten Ryttersgaard, Søren Christian Schou, Anette Graven Sams
-
Patent number: 8367390Abstract: The present invention relates to variants of Glycoside Hydrolase family 53 galactanases, e.g., variants of the galactanases from strains of Yersinia, Aspergillus, Humicola, Meripilus, Myceliophthora, Thermomyces, Bacillus, Bifidobacterium, Cellvibrio, Clostridium, Pseudomonas, Thermotoga, or Xanthomonas.Type: GrantFiled: April 8, 2009Date of Patent: February 5, 2013Assignee: Novozymes A/SInventors: Leonardo De Maria, Allan Svendsen, Torben Vedel Borchert, Lars Lehmann Hylling Christensen, Sine Larsen, Carsten Ryttersgaard
-
Publication number: 20120178740Abstract: The invention relates to compounds of general formula (I) wherein A, R1, R2, R3, R4, R5, R9, m and n are defined as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, as JAK kinase and protein tyrosine kinase inhibitors for preventing, treating or ameliorating diseases and complications thereof, including, for example, psoriasis, atopic dermatitis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes, asthma, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases and indications where immunosuppression would be desirable for example in organ transplantation.Type: ApplicationFiled: July 8, 2010Publication date: July 12, 2012Applicant: LEO PHARMA A/SInventors: Simon Feldbæk Nielsen, Daniel Rodriguez Greve, Carsten Ryttersgaard, Gunnar Grue-Sørensen, Erik Rytter Ottosen, Tina Dahlerup Poulsen, Søren Christian Schou, Anthony Murray
-
Patent number: 7537921Abstract: Variants of Glycoside Hydrolase family 53 galactanases, e.g. variants of the galactanases from strains of Yersinia, Aspergillus, Humicola, Meripilus, Myceliophthora, Thermomyces, Bacillus, Bifidobacterium, Cellvibrio, Clostridium, Pseudomonas, Thermotoga, or Xanthomonas.Type: GrantFiled: December 11, 2003Date of Patent: May 26, 2009Assignee: Novozymes A/SInventors: Leonardo De Maria, Allan Svendsen, Torben Vedel Borchert, Lars Lehmann Hylling Christensen, Sine Larsen, Carsten Ryttersgaard